Study Overview: This study explores the use of ACR-368 for treating specific cancers: ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. It checks how well ACR-368 works and its safety. There are two groups in this study. People in one group get ACR-368 alone, while the other group gets ACR-368 with a small dose of another drug called gemcitabine. The selection to these groups depends on a special test result called the OncoSignature® test.
Complex Terms Explained:
- Ovarian Carcinoma: A type of cancer that begins in the ovaries.
- Endometrial Adenocarcinoma: Cancer that starts in the lining of the uterus.
- Urothelial Carcinoma: Cancer that starts in the bladder or urinary system.
- Gemcitabine: A medication used to treat various cancers.
Participation Considerations:
- Participants will be treated until cancer progresses or side effects become too severe.
- Eligibility requires confirmed cancer that has not responded to earlier treatments.
- Participants must provide tumor samples and have stable health conditions.
This study aims to find better treatments for these serious cancers and is looking for participants who meet specific health criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand